Short Summary
The plaintiffs, Astrazeneca Ab, filed a suit alleging that the defendant, Westcoast Pharmaceutical Works Limited, was infringing their Indian Patent IN 297581, which covers the anticancer drug Osimertinib (marketed as Tagrisso). The plaintiffs claimed the defendant was soliciting large orders to manufacture and sell the infringing product without authorization.
Detailed Summary
In the high-stakes world of pharmaceuticals, a single patent can be the difference between a blockbuster drug and a generic copycat. When a competitor begins soliciting large orders for a patented anticancer drug without permission, the original innovator doesn't just lose revenue—it loses the very foundation of its investment in research and development. This case between AstraZeneca and Westcoast Pharmaceutical Works is a stark reminder that patent infringement isn't only about manufacturing; it can begin the moment you start courting buyers for an unauthorized product.
AstraZeneca AB, the global pharmaceutical innovator behind the breakthrough anticancer drug Osimertinib—sold under the brand name Tagrisso—held Indian Patent IN 297581 covering the compound. The plaintiffs alleged that Westcoast Pharmaceutical Works Limited, a domestic pharmaceutical company, was actively soliciting large orders to manufacture and sell a product that fell squarely within the scope of AstraZeneca's patented invention, all without seeking any license or authorization. This unauthorized commercial activity prompted AstraZeneca to approach the court seeking urgent relief to stop the alleged infringement in its tracks.
AstraZeneca argued that Westcoast's act of soliciting large orders for the infringing product constituted a clear violation of their patent rights. The plaintiffs contended that even before actual manufacture or sale, the very act of courting buyers for an unlicensed version of Osimertinib amounted to infringement under Indian patent law. The plaintiffs presented averments in their plaint aimed at establishing that Westcoast was preparing to enter the market with a product covered by their exclusive patent rights. The defendant, Westcoast Pharmaceutical Works, faced allegations of attempting to commercially exploit a patented anticancer drug without any license, authorization, or arrangement with the patent holder.
The court examined the averments made in the plaint and concluded that the plaintiffs had succeeded in making out a prima facie case of patent infringement. Finding sufficient grounds to believe that Westcoast's activities threatened to violate the exclusive rights granted under Indian Patent IN 297581, the court granted an interim injunction in favor of AstraZeneca. This interim order effectively restrained Westcoast from proceeding with the alleged infringing activities while the matter awaited fuller adjudication, providing AstraZeneca with immediate protection of its patent rights.
For founders and IP professionals in the pharmaceutical and life sciences space, this case delivers a critical lesson: patent infringement is not limited to the moment of manufacture or sale. Soliciting orders, courting buyers, or preparing to commercialize a patented product without authorization can itself trigger infringement liability. Before launching any generic version of a patented drug—or even marketing or accepting orders for one—conduct thorough freedom-to-operate analyses and confirm that the patent has expired, been invalidated, or that a valid license is in place. Proactive patent due diligence is far cheaper than defending an interim injunction in court.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before Delhi High Court - Orders. Understanding the court's reasoning in Astrazeneca Ab vs Westcoast Pharmaceutical Works Limited is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
V.V. Sivaram And Ors.vsFoseco India Limited
The plaintiff, holding patents for 'Turbostop,' a specialized contoured impact pad used in steel plants, sought an injunction against the defendants (former employees and associated entities). The dispute centered on whether the defendants were manufacturing and marketing a product identical to Turbostop using confidential know-how obtained during their employment.
Nokia Technologies OYvsAssistant Controller of Patents and Designs
Nokia Technologies OY appealed the Assistant Controller's refusal to grant a patent for its system and method for listening to audio content. The appellant argued that the refusal order failed to consider their amended claims and responses to objections raised under Section 3(k).
Kanishk SinhavsState Of West Bengal & Ors.
Kanishk Sinha, the patent holder of e-rickshaws/e-vehicles, appealed a judgment that had previously directed registration authorities to register these vehicles. The court held that questions regarding exclusive rights, compulsory licensing, and compensation are matters for pending civil suits or statutory fora under the Patents Act, not writ jurisdiction.
F.Hoffmann-La Roche LtdvsNatco Pharma Limited
F.Hoffmann-La Roche Ltd filed a petition seeking the revocation of Patent No. 236791 from the patent register. However, the petitioner subsequently instructed their counsel to withdraw the petition.
Vertex Pharmaceuticals IncorporatedvsController General Of Patents, Design, Trademark and Geographical Indications & Ors.
Vertex Pharmaceuticals Incorporated filed a petition challenging a notice issued regarding a pre-grant opposition filed by respondent no. 3 against its Indian Patent Application. Vertex claims that the opposition could not have been filed after the Controller had already decided to proceed with the grant of the patent.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.